Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer.
Braman N, Prasanna P, Whitney J, Singh S, Beig N, Etesami M, Bates DDB, Gallagher K, Bloch BN, Vulchi M, Turk P, Bera K, Abraham J, Sikov WM, Somlo G, Harris LN, Gilmore H, Plecha D, Varadan V, Madabhushi A. · 2019
Read Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer. by Braman N, Prasanna P, Whitney J, Singh S, Beig N, Etesami M, Bates DDB, Gallagher K, Bloch BN, Vulchi M, Turk P, Bera K, Abraham J, Sikov WM, Somlo G, Harris LN, Gilmore H, Plecha D, Varadan V, Madabhushi A. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6481453.txt.
Introduction
Braman and co-authors ask whether the MRI appearance of a breast tumor and its rim can reveal the tumor's molecular subtype and treatment prospects. In HER2-positive breast cancer, under 35 percent of patients respond fully to trastuzumab, and the HER2-enriched subtype, 40 to 50 percent of cases, responds best, but no accepted imaging biomarker exists.
In 209 patients, radiomic features from inside the tumor and the peritumoral zone distinguished the HER2-enriched subtype. Among patients receiving HER2-targeted therapy before surgery, the same signature tracked actual pathologic response. Reading the neighborhood, not just the mass, carried the signal, suggesting radiology can proxy for genomic tests where those are unavailable.
Catalog record
| CREATOR | Braman N, Prasanna P, Whitney J, Singh S, Beig N, Etesami M, Bates DDB, Gallagher K, Bloch BN, Vulchi M, Turk P, Bera K, Abraham J, Sikov WM, Somlo G, Harris LN, Gilmore H, Plecha D, Varadan V, Madabhushi A. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer By Nathaniel Braman, Prateek Prasanna, Jon Whitney, Salendra Singh, Niha Beig, Maryam Etesami, David D B Bates, Katherine Gallagher, B Nicolas Bloch, Manasa Vulchi, Paulette Turk, Kaustav Bera Published in: JAMA Network Open DOI: 10.1001/jamanetworkopen.2019.2561 ABSTRACT Key Points Question Can quantitative imaging features extracted from the tumor and tumor environment on breast magnetic resonance imaging characterize tumor biological features relevant to outcome of targeted therapy? Findings In this diagnostic study of 209 patients, among HER2 (ERBB2)-positive breast cancers, an intratumoral and peritumoral imaging signature capable of discriminating the response-associated HER2-enriched molecular subtype was identified. When evaluated among recipients of HER2-targeted therapy, this signature was found to be associated with response to neoadjuvant chemotherapy. Meaning Quantitative analysis of the tumor and its surroundings may provide valuable cues into breast cancer biological features and likelihood of response to targeted therapy. INTRODUCTION Human epidermal growth factor receptor 2 (currently known as ERBB2, but referred to as HER2 in this study)–positive breast cancer is morphologically and genetically heterogeneous. Not all patients will fully benefit from HER2-targeted treatment, with less than 35% of patients initially responding to therapy with the monoclonal antibody trastuzumab.1,2 Molecular profiling via tests such as the PAM50 gene set can provide insight into treatment response by subcategorizing HER2-positive (HER2+) tumors into response-associated intrinsic molecular subtypes.3,4,5,6,7,8 The HER2-enriched (HER2-E) subtype, composing 40% to 50% of HER2+ breast cancers, is of particular therapeutic interest owing to its elevated rate of response to HER2-targeted therapy.3,9,10 Although molecular subtyping of HER2+ breast cancer is gradually gaining biological significance, no clinically accepted biomarkers are as yet available for prediction of response to anti-HER2 therapy.11 Therefore, there remains a need to develop novel approaches to estimate clinical outcomes of HER2-targeted therapy. In breast cancer, computerized tissue phenotyping on radiographic imaging (or radiomic) features extracted from breast magnetic resonance imaging (MRI) has been shown to be sensitive to many facets of cancer biological factors, such as clinical receptor status,12,13,14,15,16,17,18,19,20 genotypic molecular subtype,21,22,23 and gene mutation or molecular pathway activation.24,25,26,27,28,29 Although some recent approaches have explored direct radiomic estimation of response from pretreatment30,31 and interim MRI,19,32,33 these approaches often lack well-understood associations with underlying tumor biological factors. While a number of other investigations involving breast radiogenomics (ie, integrating radiomic and genomic data for multiscale tumor characterization) have interrogated biological associations with imaging,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28 relatively little of this work25,27 has also placed such findings in the context of clinical outcomes. Thus, the association of radiogenomic signatures with response to targeted therapies remains largely unknown. Similarly, almost all radiogenomic approaches have focused on molecular and genomic correlations with imaging features and not explicitly considered the association of radiomic features with histopathologic attributes. A radiogenomic approach to response assessment, leveraging radiomic signatures of response-associated molecular subtypes with a known morphologic basis, could inform therapeutic approach while still providing biological interpretability. A growing body of research implicates the tumor microenvironment as a key player in breast cancer development and progression.34 Physical and genetic changes within the stroma surrounding a tumor help dictate its ability to grow and spread, evade the body’s immune defenses, and resist therapeutic intervention. Empirical evidence suggests35 that the microenvironment might harbor information that enables estimation of treatment response. For instance, an elevated concentration of tumor-infiltrating lymphocytes within the stroma is associated with improved therapeutic outcome in HER2+ breast cancer,36 and differing immunogenicity between HER2+ molecular subtypes of breast cancer has been shown to contribute to their varying treatment outcomes.4,37,38 The case for considering the tumor microenvironment is especially strong in the stratification of HER2+ by molecular subtype and outcome, as it has recently been shown that HER2-E and non–HER2-E differ in their interactions with the tumor microenvironment that potentially contribute to therapeutic resistance.39 Despite the biological significance of the tumor microenvironment, most breast radiomics approaches have focused on interrogating heterogeneity patterns across the entire tumor40 or within intratumoral subregions on breast MRI.41 Others have reported success of such approaches within the bulk parenchyma on dynamic contrast enhanced (DCE)–MRI13,22,23,42,43,44,45 and other modalities,43 indicating the presence of discriminating radiomic information outside of the lesion. In addition, architectural disorder of the surrounding tumor-associated vessel network was recently shown to be associated with treatment response on pretreatment DCE-MRI.46 Comparatively few studies,23,25,30,47 however, have explored textural measures of heterogeneity within the tumor environment in immediate proximity to the tumor on breast DCE-MRI. This region has been shown to qualitatively differ in appearance on DCE-MRI across intrinsic molecular subtypes of breast cancer15 and, thus, radiomic analysis of this region may contribute value to the identification of the HER2-E subtype. In previous work, supplementing analysis of the tumor with peritumoral radiomics—textural measurements within the tissue surrounding the tumor—enabled the estimation of treatment response on pretreatment DCE-MRI.30 One hypothesis for the estimative capability of peritumoral radiomics is that these features might detect the magnitude of pretreatment immune response and spatial architecture of lymphocytes within the tumor environment.30 In this study, we evaluated response-associated subtypes of HER2+ breast cancer by interrogating the tumor and peritumoral environment on imaging. We then examined a possible association between radiogenomic signature of HER2-E and response to HER2-targeted neoadjuvant chemotherapy (NAC) in 2 independent validation cohorts. We also explored the underlying biological basis of this distinctive radiomic signature through a quantitative comparison with pathologic immune response. Our approach represents several possible contributions to the area of breast radiogenomics: (1) radiogenomic subtyping of HER2+ breast cancer using both intratumoral and peritumoral textural patterns, (2) applying radiogenomic subtyping to the assessment of response to a specific targeted therapy, and (3) substantiating radiogenomic signatures through morphologic association with corresponding biopsy samples. METHODS Data Sets and Experiments The flowchart in Figure 1 depicts an overview of the data sets used in this study and the various experiments performed. Clinical and scan information for each cohort is either described in a previous publication30 or included in Table 1. The analysis included 209 patients (mean [SD] age, 51.1 [11.7] years). This Health Insurance Portability and Accountability Act of 1996 regulations–compliant study was approved by the institutional review board at the University Hospitals Cleveland Medical Center, Cleveland, Ohio, and the need for informed consent was waived; a correlative study was also conducted after review and approval by the University Hospitals Cleveland Medical Center Institutional Review Board. This study followed the Standards for Reporting of Diagnostic Accuracy (STARD) reporting guideline. The study was conducted from April 27, 2012, through September 4, 2015, and data analysis was performed from January 15, 2017, to February 14, 2019. [Figure: Experimental DesigneFigure 2 in the Supplement depicts the process of developing imaging signatures associated with receptor status (experiment 1) and HER2+ molecular subtype (experiment 2). HER2-E indicates HER2-enriched; HR, hormone receptor; pCR, pathologic complete response; PRC1, pathologic response cohort 1; PRC2, pathologic response cohort 2; and TN, triple negative.] [Table: Clinical Information for the BrUOG 211B/TCIA Molecular Subtype Discovery Cohort and PRC1 and PRC2] Distinguishing Receptor Subtypes A previously described cohort of 117 patients30 who received neoadjuvant treatment at University Hospitals Cleveland Medical Center was used to first assess the ability of peritumoral radiomics to differentiate HER2+ from breast cancers of other receptor statuses. This cohort contained